病毒学
肝细胞癌
乙型肝炎病毒
免疫疗法
医学
嵌合抗原受体
乙型肝炎
抗原
T细胞
肝硬化
免疫学
病毒
免疫系统
癌症研究
内科学
作者
Anthony T. Tan,Sophia Schreiber
标识
DOI:10.1016/j.antiviral.2020.104748
摘要
Chronic hepatitis B virus (HBV) infection remains a major global concern due to its high prevalence and the increased probability of progressing toward cirrhosis and hepatocellular carcinoma (HCC). While currently available therapies are effective in controlling HBV replication, they rarely achieve functional cure. Similarly, effective treatment options for HBV-related HCC (HBV-HCC) are limited and primarily applicable only for early stages of the disease. With the general success of chimeric antigen receptor T-cell immunotherapy against B-cell leukemia, adoptively transferring engineered autologous T cells specific for HBV or HCC antigens might represent a promising therapeutic approach for both chronic HBV infection and HBV-HCC. This review will describe the novel T cell-related immunotherapies being developed for both indications and discuss the approach of each strategy, their considerations and limitations when applied for treatment of chronic HBV infection (CHB) and HBV-HCC.
科研通智能强力驱动
Strongly Powered by AbleSci AI